<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50237">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858129</url>
  </required_header>
  <id_info>
    <org_study_id>0090-11-BNZ</org_study_id>
    <nct_id>NCT01858129</nct_id>
  </id_info>
  <brief_title>Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn</brief_title>
  <official_title>Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn in Infants Born at &gt;34 Weeks Gestation: A Prospective, Randomized, Double Blind, Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient Tachypnea of the Newborn (TTN) is a common respiratory disorder affecting late
      preterm and term babies caused by lung edema resulting from delayed absorption of fetal
      alveolar lung fluid.

      The investigators hypothesize that ENAC expression will be up-regulated as a result of
      administration of corticosteroids. This effect will lead to enhanced absorption of fetal
      lung fluid finally treating TTN. The aim of our study will be to evaluate whether inhaled
      corticosteroids reduce respiratory distress and morbidity in late preterm and term neonates
      presenting with TTN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome measure will be the assessment of respiratory distress reflected by TTN
      clinical score in neonates presenting with TTN and treated with inhaled corticosteroids
      compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of respiratory distress</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure will be the assessment of respiratory distress reflected by TTN clinical score in neonates presenting with TTN and treated with inhaled corticosteroids compared to placebo at 12, 24 and 48 hours after the first dose of inhaled study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome will be the assessment of morbidity associated with TTN</measure>
    <time_frame>An average time period expected to be 5 days, according to the duration of hospital stay</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary outcome will be the assessment of morbidity associated with TTN as reflected by time to spontaneous unsupported breathing of room air (hours), time to spontaneous breathing (LFNC and/or FiO2&lt;0.3) for infants who got a higher level of respiratory support,  maximal level of respiratory support (no oxygen, intra-incubator oxygen, LFNC, nCPAP, NIPPV, high flow nasal canulla, SIMV, HFOV), LOS (days), TFF (hours),  need and length of antibiotic therapy in the study vs. placebo groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Will follow blood pressure</measure>
    <time_frame>An average time period expected to be 5 days, according to the duration of hospital stay</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood pressure measurements</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Transient Tachypnea of the Newborn</condition>
  <arm_group>
    <arm_group_label>Inhaled steroids (Budicort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Budicort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled NS 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental group: Budicort by Inhalation</intervention_name>
    <description>Inhaled Budicort twice daily</description>
    <arm_group_label>Inhaled steroids (Budicort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Late preterm and term infants (post-menstrual age â‰¥ 34 weeks) delivered by cesarean
             section or vaginal delivery

          -  Diagnosis of TTN

          -  Parents signed informed consent

        Exclusion Criteria:

          -  Meconium aspiration syndrome

          -  Respiratory distress syndrome

          -  Congenital heart disease

          -  Non respiratory disorders causing tachypnea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Kugelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai Zion Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Kugelman, MD</last_name>
    <email>amirkug@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Bader, MD</last_name>
    <email>davidbade@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Kugelman, MD</last_name>
      <phone>972-4-8359559</phone>
      <email>amirkug@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>David Bader, MD</last_name>
      <phone>972-4-8359559</phone>
      <email>davidbade@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Bader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 20, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bnai Zion Medical Center</investigator_affiliation>
    <investigator_full_name>Kugelman Amir</investigator_full_name>
    <investigator_title>Head, Pediatric Pulmonary Unit</investigator_title>
  </responsible_party>
  <keyword>TTN</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
